Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF) | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 In Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Sub-indication: Idiopathic Pulmonary Fibrosis (IPF)

Study Type: Drug Study

Principal Investigator: John McConnell, M.D.
Norton Pulmonary Specialists

Sponsor: Sponsor: Nitto Denko Corporation

Learn more at ClinicalTrials.gov

Email for more information: NCRG@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial

Schedule an Appointment